Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102885 | 0.83 | SMN1; SMN2 (0.42) | USP2SMN1; SMN2BUB1KDM4EMAPT | |
| SCHEMBL5560408 | 0.74 | BCHE (0.46) | SMN1; SMN2KDM1ABCHEGPR119HDAC1 | |
| SCHEMBL29380399 | 0.74 | BCHE (0.46) | SMN1; SMN2KDM1ABCHEGPR119HDAC1 | |
| SCHEMBL31218507 | 0.72 | CHRM2 (0.44) | USP2SMN1; SMN2BUB1KDM4EMAPT | |
| SCHEMBL993758 | 0.72 | NR1H2 (0.43) | PREPUSP2SMN1; SMN2KDM4EMAPT | |
| SCHEMBL20604086 | 0.71 | P2RX4 (0.39) | SMN1; SMN2BCHE | |
| SCHEMBL3110330 | 0.71 | MAPT (0.36) | PREPUSP2SMN1; SMN2BUB1KDM4E | |
| SCHEMBL8014569 | 0.71 | BCHE (0.47) | USP2SMN1; SMN2BUB1KDM4EMAPT | |
| SCHEMBL4796997 | 0.71 | CHRM2 (0.43) | USP2SMN1; SMN2BUB1KDM4EMAPT | |
| SCHEMBL7378278 | 0.71 | USP2 (0.46) | USP2SMN1; SMN2KDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930872-A | Catalyst system, prepolymerized catalyst composition and olefin polymerization process | 中国石油化工股份有限公司 | 2025-05-06 | — | — | CN | claimed |
| US-20030055297-A1 | An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation | ABBOTT LABORATORIES | 2003-03-20 | — | — | US | claimed |
| CN-119930869-A | Auxiliary agent for olefin polymerization, olefin catalyst system, prepolymerized catalyst composition and olefin polymerization method | 中国石油化工股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119930872-A | Catalyst system, prepolymerized catalyst composition and olefin polymerization process | 中国石油化工股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2025-02-20 | — | — | US | disclosed |
| EP-4472963-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | Arvinas Operations, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118946556-A | DGK targeting compounds and uses thereof | 阿维纳斯运营公司 | 2024-11-12 | — | — | CN | disclosed |
| WO-2024191988-A1 | 3,4-FUSED BICYCLIC PYRROLIDINE AND 3,4-FUSED BICYCLIC PYRROLIDINONE COMPOUNDS | CYTEIR THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| CN-117658987-A | Compounds as PLK1 inhibitors, and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-20070155792-A1 | Peptide Deformylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| US-20070155792-A1 | Peptide Deformylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| EP-0937032-B1 | SUBSTITUTED GAMMA AMINOBUTYRIC ACIDS AS PHARMACEUTICAL AGENTS | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-0937032-B1 | SUBSTITUTED GAMMA AMINOBUTYRIC ACIDS AS PHARMACEUTICAL AGENTS | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20030055297-A1 | An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation | ABBOTT LABORATORIES | 2003-03-20 | — | — | US | disclosed |
| WO-2002081441-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRROLIDINE NEURAMINIDASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-10-17 | — | — | WO | disclosed |
| US-6153650-A | TREATMENT OF EPILEPSY, FAINTNESS ATTACKS, HYPOKINESIA, CRANIAL DISORDERS, NEURODEGENERATIVE DISORDERS, DEPRESSION, ANXIETY, PANIC, PAIN, NEUROPATHOLOGICAL DISORDERS, INFLAMMATION, AND GASTROINTESTINAL DAMAGE. | WARNER-LAMBERT COMPANY (US) | 2000-11-28 | — | — | US | disclosed |
| EP-0937032-A1 | SUBSTITUTED GAMMA AMINOBUTYRIC ACIDS AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998017627-A1 | SUBSTITUTED GAMMA AMINOBUTYRIC ACIDS AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | PREP 2667/4885USP2 4138/4885SMN1; SMN2 4448/4885 |
| US-20070155792-A1 | Peptide Deformylase Inhibitors | PDF, PEPD, DPEP1 | PREP 7/4885USP2 1733/4885SMN1; SMN2 2376/4885 |
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | PREP 2667/4885USP2 4138/4885SMN1; SMN2 4448/4885 |
| US-20030055297-A1 | An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation | NEU4, NEU2, NEU1 | PREP 146/4885USP2 2601/4885SMN1; SMN2 4069/4885 |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | PREP 2667/4885USP2 4138/4885SMN1; SMN2 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.